CELLULOSE ANTIGEN RECEPTORS SHOW SPECIFICITY TO B CELL ADULT ANTIGENS AND THEY CONTAIN PHARMACEUTICALS

VN10062260BActive Publication Date: 2026-11-02REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
VN1202402431
Authority / Receiving Office
VN · VN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2019-07-18
Publication Date
2026-11-02
Estimated Expiration
2039-07-18
Patent Text Reader

Abstract

The invention relates to B-cell mature antigen (BCMA) expressed on malignant plasma cells. The invention relates to BCMA-specific mosaic antigen receptors and cells expressing these mosaic antigen receptors. By the defined scheme, engineered cells expressing the mosaic antigen receptors in this invention are capable of inhibiting the growth of BCMA-expressing tumors. The engineered cells in this invention are useful in the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desirable and / or therapeutically beneficial. For example, the engineered cells expressing BCMA-specific mosaic antigen receptors in this invention are useful in the treatment of various cancers, including multiple myeloma.
Need to check novelty before this filing date? Find Prior Art